Contact Us
Drug Search Results
More Filters [+]

Pexelizumab

Alternative Names: pexelizumab
Latest Update: 2022-10-26
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: C5 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Procter and Gamble
Company Location: CINCINNATI OH 45202
Company CEO: Jon R. Moeller
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pexelizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Myocardial Infarction|Inflammation|Heart Failure|Myocardial Ischemia|Coronary Artery Disease|Heart Block|Pulmonary Infarction|Chest Pain|Myocardial Reperfusion Injury

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
APEX-AMI

P3

Completed

Myocardial Infarction

2007-05-01

54%
APEX-AMI

P3

Terminated

Myocardial Ischemia|Myocardial Reperfusion Injury|Myocardial Infarction

2006-08-08

PRIMO-CABG II

P3

Completed

Myocardial Infarction|Pulmonary Infarction

2006-02-01

PRIMO-CABG II

P3

Completed

Coronary Artery Disease

2005-10-01

40%

Recent News Events

Date

Type

Title

10/26/2022

PubMed

 Eisosome disruption by noncoding RNA deletion increases protein secretion in yeast.

06/27/2022

PubMed

 Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials.

07/14/2021

PubMed

 Expression of antibody fragments in Saccharomyces cerevisiae strains evolved for enhanced protein secretion.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions